Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420856 | 0.82 | PTGS2 (0.53) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL19014652 | 0.79 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL22560752 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL1959392 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL22560741 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL24775450 | 0.78 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL24896301 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL21851539 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL19183275 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL23298661 | 0.77 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1BCL2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2613769-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Abbvie Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012121758-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |